Glucosamine use is associated with a 25% higher risk of progressing from mild cognitive impairment to dementia, according to University of Florida researchers. The study, published June 9 in Nature Metabolism, suggests the supplement may interfere with metabolic pathways in the brain, potentially accelerating the progression of Alzheimer’s disease.
Why is glucosamine linked to dementia risk?
Researchers at the University of Florida (UF) identified a correlation between glucosamine supplementation and faster cognitive decline. Using artificial intelligence to analyze deidentified UF Health records from 2012 to 2024, the team examined patients diagnosed with Alzheimer’s disease and related dementias (ADRD) or mild cognitive impairment (MCI).
The analysis revealed that approximately 8% of patients in both the ADRD and MCI groups reported taking glucosamine. After adjusting for age, sex, and demographics, the data showed that patients with MCI who used the supplement were 25% more likely to develop dementia.
The impact appears to change as the disease advances. While the primary risk for MCI patients was progression to dementia, the study found a 25% increase in mortality risk among patients already diagnosed with ADRD who used glucosamine. Researchers noted that no similar mortality increase was observed among those with only MCI.
Most commercial glucosamine supplements are derived from natural sources like corn or the shells of shellfish. Because glucosamine is a sugar-related molecule, it can cross the blood-brain barrier.
How does glucosamine affect the brain’s metabolism?
The study suggests that glucosamine may disrupt a specific biological process involving protein and sugar-tagging. In a healthy brain, these “tags” help proteins fold correctly and perform essential cellular functions. However, the UF team found that this pathway becomes excessively active in the presence of Alzheimer’s disease.
“Our results suggest that altered metabolism is a significant contributor to Alzheimer’s progression,” said Ramon Sun, Ph.D., senior author and director of the Center for Advanced Spatial Biomolecule Research at UF’s McKnight Brain Institute.
Matt Gentry, Ph.D., chair of UF’s Department of Biochemistry and Molecular Biology, noted that the Alzheimer’s brain may be uniquely vulnerable to these metabolic disruptions. “The Alzheimer’s brain is adding too many of these sugar structures, and this seems to contribute to the disease rather than protect against it,” Gentry said.
Evidence from animal and human tissue models
To test this hypothesis, researchers conducted experiments on genetically modified mice. The results showed that glucosamine increased the attachment of sugar molecules to proteins within cells. These mice also exhibited worsening deficits in social memory, which is the ability to recognize and remember others.
The researchers were able to reverse some of these effects by chemically reducing the sugar-tagging activity, which improved memory performance in the mice. This suggests that the metabolic pathway itself could be a target for future medical intervention.
The team also analyzed human brain tissue from the UF Neuromedicine Brain and Tissue Bank. In collaboration with Stefan Prokop, M.D., researchers found that Alzheimer’s brain specimens contained significantly higher levels of protein sugar-attachment compared to healthy control samples.
What are the next steps for Alzheimer’s research?
While the findings are significant, the researchers emphasized that this study shows an association and does not prove that glucosamine causes dementia. Clinical trials are required to confirm whether the supplement directly triggers these metabolic changes in humans.
The discovery highlights a shift in how scientists view neurodegenerative diseases. Rather than focusing solely on the buildup of amyloid plaques and tangles, researchers are looking closer at metabolic dysfunction. Addressing these metabolic defects could eventually serve as a complement to existing Alzheimer’s treatments.
If you are currently taking over-the-counter supplements for joint pain, consult your neurologist or primary care physician to discuss how they might interact with your specific cognitive health profile.
Frequently Asked Questions
Does glucosamine cause Alzheimer’s disease?
The study found an association between glucosamine use and faster disease progression, but it did not prove causality. Clinical trials are needed to determine if the supplement directly causes the disease.
Who is most at risk according to this study?
The research specifically highlighted individuals with mild cognitive impairment (MCI) and those already diagnosed with Alzheimer’s disease and related dementias (ADRD).
What is the “sugar-tagging” pathway?
It is a metabolic process where sugar molecules are attached to proteins to help them function. The study suggests this process becomes overactive in Alzheimer’s-affected brains.
Stay informed on the latest medical breakthroughs. Subscribe to our newsletter or share this article with someone who may find it helpful.
